Opana (Oxymorphone) Therapeutic Overview

Opana (oxymorphone) is an extended-release formulation indicated for the management of pain. The medication is reserved for individuals experiencing pain that is substantial enough to require daily, around-the-clock opioid treatment for an extended period. This treatment pathway is considered when other pain management options, such as non-opioid analgesics or immediate-release opioids, have been determined to be inadequate or ineffective for the patient.

Key therapeutic applications include addressing persistent, moderate-to-severe pain. The extended-release profile supports continuous pain management throughout the day. The selection of patients for this treatment follows established clinical principles for long-term opioid analgesic use.

It is important to note that Opana is not intended for short-term pain relief, mild discomfort, or use on an as-needed basis. Its role is strictly defined within the context of long-term pain management for patients who meet the specific requirements outlined in clinical guidelines.

---

Quick Facts

• Targeted Condition: Moderate to severe pain.
• Usage Context: Management of persistent pain requiring continuous, around-the-clock opioid treatment.
• Application Criteria: Reserved for use when alternative options are inadequate.
• Duration: Intended for an extended period of time.

Eligibility and Contraindications for Opana Use

Official regulatory documentation establishes strict limits on who may and may not use Opana (oxymorphone hydrochloride) based on pre-existing conditions and concurrent medications. The medicine is contraindicated and must not be used in several specific patient populations, primarily those with severely compromised respiratory function. This includes patients experiencing significant respiratory depression or those with acute or severe bronchial asthma in unmonitored settings.

Non-eligibility also extends to individuals with a known or suspected gastrointestinal obstruction, such as paralytic ileus, or those with moderate or severe hepatic (liver) impairment. Furthermore, patients with a known hypersensitivity to oxymorphone or morphine analogs are excluded. Concomitant use with Monoamine Oxidase Inhibitors (MAOIs), or within 14 days of discontinuing an MAOI, is strictly avoided due to the risk of potentiating effects.

Use is restricted, requiring extreme caution, in patients with less severe conditions, such as mild hepatic or any degree of renal impairment, who generally require a reduced initial dose and close monitoring. Geriatric patients also require lower doses and close monitoring due to increased risk of respiratory depression. The safety and effectiveness of the extended-release formulation have not been established in pediatric patients.

Opana Interactions with Other Medicines and Products

Official regulatory information emphasizes several categories of clinically significant interactions associated with this medication.

Pharmacodynamic and Exposure-Altering Interactions

The most serious documented risk involves concomitant use with Central Nervous System (CNS) Depressants, including alcohol, benzodiazepines, other opioids, sedatives, and tranquilizers. This combination can result in additive effects, leading to profound sedation and severe respiratory depression. Regulatory guidelines stipulate that co-prescribing with these agents must be done with limited dosages and durations, and patients require close monitoring.

Interactions with Monoamine Oxidase Inhibitors (MAOIs) necessitate a strict constraint: co-administration must be avoided, and a 14-day washout period is required after stopping MAOIs due to the risk of potentiating the drug's effects.

Other Significant Combinations

• Mixed Agonist/Antagonist or Partial Agonist Opioid Analgesics: Use with drugs like nalbuphine or pentazocine is restricted as it may reduce the primary drug's analgesic effect or precipitate withdrawal symptoms.
• Serotonergic Drugs: Combining with agents like SSRIs or triptans is associated with the risk of serotonin syndrome, and the medication must be discontinued if this condition is suspected.
• Anticholinergics: Co-administration may increase the risk of severe gastrointestinal effects, including paralytic ileus.

Consumption of alcohol or any product containing alcohol is strictly discouraged, as this co-ingestion can result in a significant, potentially fatal rise in plasma concentration.

Mu-Opioid Receptor Agonism

Oxymorphone primarily acts as a selective agonist on mu-opioid receptors (MOR) located throughout the central nervous system, including the brain and spinal cord. Binding to MOR initiates a G-protein-coupled signaling cascade that closes voltage-gated calcium channels and opens potassium channels. This dual action reduces neuronal excitability and the release of nociceptive neurotransmitters (like substance P and glutamate) from the presynaptic terminal. The resulting hyperpolarization of the neuron strongly inhibits pain signal transmission within afferent pathways.

Modulating Descending Pain Inhibitory Pathways

Beyond direct inhibition, oxymorphone engages mu-receptors on GABAergic inhibitory interneurons within supraspinal pain-modulating areas. Inhibition of these interneurons effectively disinhibits the body's natural descending pain control systems. This facilitates the flow of inhibitory signals to the spinal dorsal horn, increasing the release of endogenous mediators and thereby modulating afferent nociceptive input.

Delta-Opioid Receptor Co-Agonism

At pharmacologically relevant concentrations, oxymorphone also binds to the delta-opioid receptor (DOR) as a co-agonist. This secondary receptor engagement contributes to the overall profile by influencing the characteristics of opioid signaling within the broader nociceptive network.

How to Use Opana (Oxymorphone Extended-Release)

This section describes the administration and dosing regimen for Opana Extended-Release (ER) tablets as strictly defined in official prescribing information.

Official Administration Guidelines

The administration of Opana ER is defined by a precise schedule and specific physical conditions to ensure proper delivery of the medicine. The medicine is administered orally and is intended for patients requiring daily, around-the-clock, long-term opioid treatment, meaning it is not used on an as-needed (PRN) basis.

Entity	Instruction Principle
Route of Administration	Oral administration of the extended-release tablet.
Dosing Frequency	Administered twice daily (every 12 hours).
Timing with Meals	Must be taken on an empty stomach, defined as 1 hour prior to or 2 hours after eating.
Tablet Integrity	The tablet must be swallowed whole with sufficient water; it must not be cut, crushed, chewed, or dissolved.

Dosing and Population-Specific Rules

Initial dosing and subsequent adjustments follow fixed, low-dose starting points, particularly for certain patient populations. For an opioid-naïve adult, the initial labeled dose is typically 5 mg per dose, administered every 12 hours. Subsequent dose adjustments (titration) are made cautiously, usually in increments of 5 mg to 10 mg per dose, and only every 3 to 7 days.

Specific dosage rules are mandated for patients with reduced organ function. Patients with mild hepatic impairment or renal impairment must initiate therapy at a lower dose, such as 5 mg, or have their starting dose reduced by 50% if converting from prior opioid therapy. Similarly, administration for older adults begins with a slow, initial dose of 5 mg per dose. If therapy is to be discontinued, the total dose must be tapered gradually rather than abruptly stopped, according to official procedures.

Research Evidence / Overview of Studies

Efficacy and Symptom Management

Research has explored oxymorphone (the active ingredient in Opana) for the relief of moderate to severe pain. Studies have evaluated whether extended-release oxymorphone is associated with a reduction in chronic low back pain (CLBP) and pain related to osteoarthritis.

• Chronic Pain Trials: Randomized, double-blind, placebo-controlled trials in both opioid-naïve and opioid-experienced adult patients with CLBP examined the use of extended-release oxymorphone.
• Observed Outcomes: In these studies, pain scores were generally observed to increase significantly less in the oxymorphone group compared to the placebo group over 12 weeks of treatment.

Patient Populations Studied

Clinical trials primarily included adult patients with chronic pain conditions. Specific study populations have focused on:

Condition Studied	Patient Status
Chronic Low Back Pain	Opioid-naïve and Opioid-experienced
Osteoarthritis Pain	Suboptimally controlled on prior therapy
Postoperative Pain	Adults and adolescents (limited data)

Safety and effectiveness in the pediatric population (0 to 17 years) have not been fully established. Efficacy was not demonstrated in an open-label study involving adolescents with postoperative pain.

Long-Term Outcomes

Evidence on the long-term use of oxymorphone is currently limited, as the available research is primarily focused on short-to-medium-term data (typically up to 12 weeks of double-blind treatment). Further trials may explore long-term outcomes, especially regarding potential risks associated with extended opioid use.

Key Studies & References Efficacy and Safety of Oxymorphone Extended Release in Chronic Low Back Pain: A Randomized, Double-Blind, Placebo-Controlled Trial

Common questions about Opana (FAQ)

Q: What is Opana used to treat?

According to the official product information, Opana is an opioid agonist indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. It is generally used for patients who have already been taking an opioid medicine. The extended-release form of Opana is not intended for as-needed pain relief.

---

Q: What are the active ingredients in Opana?

The active ingredient in Opana is oxymorphone hydrochloride. This is the medicinal substance responsible for the drug's effects. The official product information specifies this compound as the core component of the medication.

---

Q: Can I take Opana if I am allergic to morphine?

Regulatory documents indicate that Opana is contraindicated in patients with a known or suspected hypersensitivity to oxymorphone or any of its ingredients. It is also not recommended for use in patients with a known hypersensitivity to morphine or other opioids. Patients are generally advised to review official warnings regarding allergies.

---

Q: Can Opana cause dependence or addiction?

As with many opioid medicines, studies and official information indicate that Opana may lead to both physical dependence and psychological dependence (addiction). Physical dependence means the body adjusts to the drug, and withdrawal symptoms may occur if the drug is stopped suddenly. This is a common and important risk associated with the use of opioid analgesics like Opana.

---

Q: Does Opana interact with alcohol?

Official product information contains a strong warning that the use of alcohol should be avoided while taking Opana. Consuming alcohol, including certain foods and beverages, can cause the body to absorb too much of the active ingredient, oxymorphone. This interaction may result in dangerously high levels of oxymorphone, potentially leading to a fatal overdose.

---

Q: Is Opana safe to take during pregnancy?

Official information states that there are no adequate and well-controlled studies of Opana in pregnant women. Prolonged use of opioid analgesics during pregnancy can result in neonatal opioid withdrawal syndrome in the newborn. The official label indicates that Opana should only be used during pregnancy if the potential benefit is considered to outweigh the potential risk to the fetus.

---

Q: Should Opana be taken with or without food?

According to the official product information for Opana Extended-Release, regulatory guidance recommends that the medicine be taken on an empty stomach. Taking it with food can significantly increase the amount of oxymorphone absorbed into the body, which may lead to an overdose. Official guidance includes specific timeframes relative to meals to ensure proper use, such as waiting one hour before or two hours after eating.

How to Store and Dispose of Opana (Oxymorphone Hydrochloride)

Official regulatory guidelines mandate strict security for Opana, a potent opioid analgesic. Due to the high risk of fatal overdose, especially from accidental ingestion by children, the medicine must be stored securely, out of sight and reach of children, and in a location not accessible by others.

Storage and Disposal Requirements

Requirement Type	Official Regulatory Statement
Storage Temperature	Store at Controlled Room Temperature.
Security Mandate	Must be stored securely and out of reach of children.
Disposal Method	Unused product must be destroyed promptly.
Primary Disposal	Use a drug take-back program if readily available.
Alternative Disposal	If a take-back program is unavailable, promptly flush the tablets down the toilet.

This specific disposal method is required for Opana to immediately remove the risk of accidental exposure in the home.